FSP-FINNISH-STEEL
23.4.2021 11:03:07 CEST | Business Wire | Press release
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland as of April 2021. Following the partnership FSP will provide Hiab Poland the surface treatment services and the expertise in development techniques.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005017/en/
The surface treatment operation in Hiab’s Stargard multi-assembly unit and its associated professionals will transfer to FSP under their current employment conditions. The purpose of the agreement is to intensify the cooperation between Hiab and FSP so that the parties can focus on their own core competencies and improve business development.
For several years, FSP has been responsible for the surface treatment of Hiab’s MULTILIFT products in Finland. We have had an intense collaboration and established joint investments with Hiab. FSP is seeking international growth. ‘Thus, intensifying the collaboration further with Hiab was an anticipated consequence’, said FSP’s Chief Executive Officer Jarno Huttunen.
The new partnership will ensure Hiab continues with the latest in desired processes and technology. The facilities are equipped with a modern, cutting edge anti-corrosion treatment production line with an option for e-coating. The number of our personnel in Poland now consists of over a hundred professionals. These factors will provide us with more prospects in the future and enhance our resilience. This of course upgrades FSP’s service level in Poland, Huttunen continued. The multi-assembly unit is in the city of Stargard, in Poland.
The extension of the cooperation between the two giants creates a competitive advantage in surface treatment quality and technological leadership.
Hiab is a part of Cargotec Corporation. Cargotec enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions.
FSP has been Hiab’s business associate for several years. FSP's role as Hiab's surface treatment expert partner is to create added value. We believe that FSP continues to respond to our demands in both delivery accuracy and quality, said Hiab’s Barry McGrane - Senior Vice President of LM Loader Cranes
Together we will continue to increase our competitive advantage in the fields of quality and technological leadership. The objective is to improve the efficiency, innovation, reliability of the surface treatment operations in the short and long term and we look forward to strengthening the partnership between both businesses,” Barry McGrane continues.
Cargotec Hiab
Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions. Hiab's class-leading load handling equipment includes HIAB, EFFER and ARGOS loader cranes, LOGLIFT and JONSERED forestry and recycling cranes, MOFFETT and PRINCETON truck mounted forklifts, MULTILIFT skip loaders and hooklifts, and tail lifts under the ZEPRO, DEL, and WALTCO brands. As the industry pioneer and with a proud 75 year history, Hiab is committed to be the preferred partner and solution provider to its customers and shape the future of intelligent load handling. www.hiab.com Hiab is part of Cargotec Corporation. www.cargotec.com
FSP Finnish Steel Painting Oy
FSP Finnish Steel Painting Oy is one of Europe's leading surface treatment companies. We employ more than 300 professionals and have a turnover of approximately EUR 26 million.
We offer industrial surface treatment and related design and value-added services. Our service covers the surface treatment process throughout the product's life cycle, from the definition of operating conditions to surface treatment, inspections and post-warranty maintenance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom